Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hepatology

Standard of Care Treatment & Clinical Trials: Your Treatment Options

At a Glance

Managing Hepatitis Delta requires specialized treatments because standard Hepatitis B medications cannot cure it. Newer drugs like Bulevirtide block the virus from entering liver cells, while emerging clinical trials aim to trap the virus and protect your liver from further damage.

Managing Hepatitis Delta (HDV) requires a specialized approach because this virus behaves differently than the more common Hepatitis B (HBV). While standard Hepatitis B medications focus on stopping HBV from replicating its DNA, they do not directly stop HDV from making copies of its RNA [1][2]. This has led researchers to develop a new generation of treatments specifically designed to target the HDV lifecycle.

Why Standard HBV Drugs Aren’t Enough

If you are already taking medications like Entecavir or Tenofovir (nucleoside analogues), you may wonder why you need additional treatment for HDV.

  • The Limitation: These drugs are excellent at suppressing HBV DNA, but HDV is an RNA virus that uses different machinery to replicate [1][3].
  • The Shell Problem: Even when HBV DNA is suppressed, the liver often continues to produce the “shell” protein (HBsAg) that HDV needs to spread [2][1].
  • The Reason to Stay on Them: Despite not killing HDV, these drugs are still vital. They keep your Hepatitis B under control, which reduces overall liver inflammation and prevents HBV from causing further damage [3][4].

Standard and Approved Treatments

For many years, Pegylated Interferon alpha (Peg-IFNα) was the only option. It works by boosting your immune system to fight the virus [5]. While it can be effective for some, it often requires a long treatment course (1–2 years) and can have significant side effects [5][6].

A major breakthrough is Bulevirtide (BLV) (pronounced boo-leh-VEER-tide), a first-in-class entry inhibitor [7].

  • How it Works: It “plugs” the NTCP receptor (the doorway) on liver cells, preventing HDV from getting inside to infect new cells [7][8].
  • Approval Status: In 2023, the European Medicines Agency (EMA) granted full marketing authorization for Bulevirtide, recognizing it as a critical therapy for HDV [9][7]. However, it may still be investigational or under review in other regions, such as the United States. Furthermore, doctors are actively studying combination therapies—such as pairing Bulevirtide with Peg-IFNα—to achieve even stronger, long-term suppression of the virus [10][11].

Emerging Therapies in Clinical Trials

Several new drugs are currently being tested in clinical trials, offering hope for more effective or better-tolerated options:

  1. Lonafarnib (Prenylation Inhibitor): (pronounced loe-NAF-ar-nib) This drug stops a specific enzyme from “gluing” the HDV virus to its HBV shell, effectively trapping the virus so it cannot be released to infect other cells [12][13].
  2. Nucleic Acid Polymers (NAPs, like REP-2139): These aim to stop the liver from releasing the HBsAg shell altogether, which would leave HDV with no way to package itself [12][14].
  3. Peginterferon lambda: A newer version of interferon that targets the liver more specifically, potentially offering the same benefits as the “alpha” version but with fewer body-wide side effects [15][16].

Treatment Path: Compensated vs. Decompensated Disease

Your treatment options depend heavily on the current health of your liver. Doctors generally divide patients into two categories:

Feature Compensated Liver Disease Decompensated Liver Disease
Liver Function The liver is scarred but can still perform its essential tasks [17]. The liver is failing and can no longer perform vital functions [18].
Symptoms Often few to no symptoms; found via testing [17]. Jaundice, fluid buildup (ascites), or confusion [18].
Typical Goal Suppress the virus to prevent further damage [19]. Stabilize the patient; often a bridge to liver transplant [18].
Common Choice Bulevirtide and/or Peg-IFNα [10][20]. Peg-IFNα is usually avoided [17]. While Bulevirtide is primarily approved for compensated disease, doctors are carefully evaluating it for some decompensated patients, and liver transplant may be considered [18][8].

This decision-making process is complex, and your care team will use your lab results and imaging to determine which path is safest and most effective for you [21][22].

Common questions in this guide

Why do I still need to take Hepatitis B medications if I have Hepatitis Delta?
Standard Hepatitis B drugs like Entecavir and Tenofovir do not cure Hepatitis Delta, but they are crucial for keeping your Hepatitis B under control. Controlling Hepatitis B reduces overall liver inflammation and prevents further damage to your liver.
What is Bulevirtide and how does it work for Hepatitis D?
Bulevirtide is a medication that acts as an entry inhibitor for the liver. It works by blocking the receptor doorway on liver cells, which prevents the Hepatitis Delta virus from entering and infecting healthy cells.
What are my treatment options if I have decompensated liver disease?
If your liver is failing, treatments like Pegylated Interferon alpha are typically avoided because they can be unsafe. Your doctor may carefully evaluate you for newer medications like Bulevirtide or consider a liver transplant.
What is Lonafarnib?
Lonafarnib is an investigational drug currently being tested in clinical trials for Hepatitis Delta. It works by stopping an enzyme that the virus uses to glue itself to its outer shell, effectively trapping the virus so it cannot spread.
How will my doctor know if my HDV treatment is working?
Your care team will monitor your progress through regular blood tests. They will specifically look for a drop in your Hepatitis Delta RNA levels and check to see if your liver enzymes, like ALT, have returned to normal ranges.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my liver disease currently considered 'compensated' or 'decompensated'?
  2. 2.What is my current HBV DNA level, and should I continue taking nucleoside analogues like Tenofovir or Entecavir?
  3. 3.Given my health history, am I a good candidate for Pegylated Interferon alpha, or should we focus on newer options like Bulevirtide?
  4. 4.Since Bulevirtide is a newer therapy, what does that mean for my insurance coverage and long-term access?
  5. 5.Are there any Phase 3 clinical trials for Lonafarnib or other emerging therapies available to me at this time?
  6. 6.How will we measure if my treatment is working—will we look for a drop in HDV RNA or normalization of my ALT levels?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus.

    Usai C, Gill US, Riddell AC, et al.

    Alimentary pharmacology & therapeutics 2022; (55(8)):978-993 doi:10.1111/apt.16807.

    PMID: 35292991
  2. 2

    Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.

    Wang W, Lempp FA, Schlund F, et al.

    Journal of hepatology 2021; (75(2)):311-323 doi:10.1016/j.jhep.2021.03.025.

    PMID: 33845061
  3. 3

    Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.

    Brancaccio G, Fasano M, Grossi A, et al.

    Alimentary pharmacology & therapeutics 2019; (49(8)):1071-1076 doi:10.1111/apt.15188.

    PMID: 30793345
  4. 4

    New actors come into play against hepatitis delta.

    Riveiro-Barciela M, Palom A, Buti M

    Revista espanola de enfermedades digestivas 2022; (114(12)):702-704 doi:10.17235/reed.2022.9050/2022.

    PMID: 36043543
  5. 5

    Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy.

    Hercun J, Kim GE, Da BL, et al.

    Alimentary pharmacology & therapeutics 2021; (54(2)):176-182 doi:10.1111/apt.16408.

    PMID: 34048594
  6. 6

    Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi.

    Butt N, Usmani MT, Hussain R, et al.

    Euroasian journal of hepato-gastroenterology 2024; (14(1)):51-55 doi:10.5005/jp-journals-10018-1431.

    PMID: 39022214
  7. 7

    Intact plasma quantification of the large therapeutic lipopeptide bulevirtide.

    Sauter M, Blank A, Stoll F, et al.

    Analytical and bioanalytical chemistry 2021; (413(22)):5645-5654 doi:10.1007/s00216-021-03384-7.

    PMID: 34018034
  8. 8

    Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.

    Jachs M, Schwarz C, Panzer M, et al.

    Alimentary pharmacology & therapeutics 2022; (56(1)):144-154 doi:10.1111/apt.16945.

    PMID: 35514008
  9. 9

    New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection.

    Sandmann L, Wedemeyer H

    Clinics in liver disease 2021; (25(4)):831-839 doi:10.1016/j.cld.2021.06.011.

    PMID: 34593156
  10. 10

    Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.

    Asselah T, Chulanov V, Lampertico P, et al.

    The New England journal of medicine 2024; (391(2)):133-143 doi:10.1056/NEJMoa2314134.

    PMID: 38842520
  11. 11

    Comparative effectiveness of seven interventions for chronic hepatitis D: a systematic review and network meta-analysis of randomized controlled trials.

    Rong Y, Ju X, Sun P, Wang Y

    BMC infectious diseases 2023; (23(1)):726 doi:10.1186/s12879-023-08718-7.

    PMID: 37880598
  12. 12

    Hepatitis delta virus: From infection to new therapeutic strategies.

    Niro GA, Ferro A, Cicerchia F, et al.

    World journal of gastroenterology 2021; (27(24)):3530-3542 doi:10.3748/wjg.v27.i24.3530.

    PMID: 34239267
  13. 13

    Emerging drugs for hepatitis D.

    Keskin O, Yurdaydin C

    Expert opinion on emerging drugs 2023; (28(2)):55-66 doi:10.1080/14728214.2023.2205639.

    PMID: 37096555
  14. 14

    Chronic Hepatitis D; at a Standstill?

    Rizzetto M

    Digestive diseases (Basel, Switzerland) 2016; (34(4)):303-7 doi:10.1159/000444467.

    PMID: 27170382
  15. 15

    Hepatitis D Review: Challenges for the Resource-Poor Setting.

    Lee AU, Lee C

    Viruses 2021; (13(10)) doi:10.3390/v13101912.

    PMID: 34696341
  16. 16

    Clinical trials in hepatitis D virus: Measuring success.

    Da BL

    Hepatology (Baltimore, Md.) 2023; (77(6)):2147-2157 doi:10.1002/hep.32732.

    PMID: 35969089
  17. 17

    Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients.

    Scheller L, Hilgard G, Anastasiou O, et al.

    Medicine 2021; (100(28)):e26571 doi:10.1097/MD.0000000000026571.

    PMID: 34260535
  18. 18

    Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D.

    Buti M, Calleja JL, Rodríguez MÁ, et al.

    Gastroenterologia y hepatologia 2025; (48(3)):502241 doi:10.1016/j.gastrohep.2024.502241.

    PMID: 39251019
  19. 19

    Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.

    Dinkelborg K, Kahlhöfer J, Dörge P, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2023; (43(8)):1663-1676 doi:10.1111/liv.15602.

    PMID: 37183524
  20. 20

    [Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis].

    Bogomolov PO, Ivashkin VT, Bueverov AO, et al.

    Terapevticheskii arkhiv 2021; (93(11)):1290-1299 doi:10.26442/00403660.2021.11.201163.

    PMID: 36286651
  21. 21

    New therapies for hepatitis delta virus infection.

    Loureiro D, Castelnau C, Tout I, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2021; (41 Suppl 1()):30-37 doi:10.1111/liv.14838.

    PMID: 34155804
  22. 22

    Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series.

    Dietz-Fricke C, Degasperi E, Jachs M, et al.

    Hepatology (Baltimore, Md.) 2024; (80(3)):664-673 doi:10.1097/HEP.0000000000000847.

    PMID: 38478755

This page provides educational information about Hepatitis Delta treatments and clinical trials. Always consult your hepatologist or care team to determine the safest and most effective treatment plan for your specific liver condition.

Get notified when new evidence is published on Hepatitis delta.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.